Filtern
Volltext vorhanden
- ja (3)
Gehört zur Bibliographie
- ja (3)
Dokumenttyp
Sprache
- Englisch (3)
Schlagworte
- Alpha therapy (1)
- Autoimmune diseases (1)
- Bone marrow transplantantation (1)
- Dickkopf proteins (1)
- Expression (1)
- Factor receptor (1)
- Graft-versus-leukemia (1)
- LRP6 (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Suppression (1)
- Tumor-necrosis-factor (1)
- WNT (1)
- antagonist (1)
- crystal structure (1)
- density (1)
- gene (1)
- growth and differentiation factor 5 (1)
- increases bone-formation (1)
- ligand (1)
- ligand-receptor complex (1)
- postmenopausal osteoporosis (1)
- rat model (1)
- receptor (1)
Institut
- Julius-von-Sachs-Institut für Biowissenschaften (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Virologie und Immunbiologie (1)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
- Medizinische Klinik und Poliklinik II (1)
- Pathologisches Institut (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
EU-Projektnummer / Contract (GA) number
- 201099 (1)
Donor CD4\(^+\)Foxp3\(^+\) regulatory T cells (T reg cells) suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT allo-HCT]). Current clinical study protocols rely on the ex vivo expansion of donor T reg cells and their infusion in high numbers. In this study, we present a novel strategy for inhibiting GvHD that is based on the in vivo expansion of recipient T reg cells before allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in T reg cell biology. Expanding radiation-resistant host T reg cells in recipient mice using a mouse TNFR2-selective agonist before allo-HCT significantly prolonged survival and reduced GvHD severity in a TNFR2-and T reg cell-dependent manner. The beneficial effects of transplanted T cells against leukemia cells and infectious pathogens remained unaffected. A corresponding human TNFR2-specific agonist expanded human T reg cells in vitro. These observations indicate the potential of our strategy to protect allo-HCT patients from acute GvHD by expanding T reg cells via selective TNFR2 activation in vivo.